A prospective, interventional case series evaluated effect of switching to aflibercept from other anti-VEGF agents in patients with incomplete response to ranibizumab and/or bevacizumab for diabetic macular edema .
Phase of Trial: Phase IV
Latest Information Update: 02 Jun 2016
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- 02 Jun 2016 New trial record